Xueming Qian
Chief Executive Officer Transcenta
Dr. Qian has nearly 30 years of industrial antibody discovery and development experience. He was Senior VP and Head of R&D of Shenogen Pharma Group. And when he worked at Amgen as principal scientist, he led multiple project teams to discover novel antibody therapeutics for the autoimmune diseases and metabolic disorders (bone and kidney). He is the leading inventor of multiple antibody patents. Dr. Qian received his B.S. in Biophysics from Fudan University, M.A. in Neuroscience/Physiology from Columbia University and Ph.D. in Neuroscience and Pharmacology from Albany Medical Center.
Seminars
It is widely considered that combination treatment is a cornerstone of cancer therapy. Therefore, this workshop will examine strategies for rational combination approaches in radioligand therapy to maximize therapeutic efficacy while minimizing toxicity. We will explore the biological rationale for pairing RLT with DDR inhibitors, immune checkpoint inhibitors, and emerging immunotherapies, including CAR-T cells. By leveraging the unique DNA-damaging properties of alpha and beta emitters, alongside agents such as DDR inhibitors, we can enhance tumor susceptibility and exploit synergistic mechanisms that amplify tumor cell killing beyond monotherapy. Join this session to guide optimal combination strategies and improve patient outcomes.
Discussion Points:
- How to minimize toxicity whilst also minimizing radiopharmaceutical dose – but
- improve efficacy?
- Establishing the timings of combination therapies – preclinical strategies to understand optimal combination partners
- Overcoming tumor resistance and sensitizing tumors to treatment
- Biomarker-driven patient selection – choosing patients most likely to benefit from specific RLT combinations
- Prioritizing target attributes beyond receptor density and expression to expand therapeutic reach
- Aligning target biology with alpha vs. beta emitter properties for more effective strategies
- Exploring novel opportunities in stromal markers like FAP and internalizing targets for durable responses
New Company for 2026
